Sanofi-Aventis DE2010/103 Dr. OUBa Abstract 5 Long - acting formulations of insulins The application relates to an aqueous pharmaceutical formulation comprising 200 1000 U/mL [equimolarto 200 - 1000 IU human insulin] of insulin glargine, with the proviso that the concentration of said formulation is not 684 U/mL of insulin glargine, 0 and its use. Lo (D~ cuc oI
